scholarly journals -SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Nicolas Lepareur ◽  
Valérie Ardisson ◽  
Nicolas Noiret ◽  
Etienne Garin
Keyword(s):  
Hepatocellular Carcinoma ◽  
Graduate School ◽  
Therapeutic Option ◽  
Potential Treatment ◽  
Cancer Centre ◽  
Metabolic Radiotherapy ◽  
Comprehensive Cancer Centre

Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 ( MeV) for the treatment of HCC. The major “milestones” of this development, from the first syntheses to the recent first injection in man, are described.

scholarly journals Telcagepant: A New Therapeutic Option for Acute Migraine?

2011 ◽  
Vol 3 ◽  
pp. CMT.S7477 ◽  
Author(s):  
E. Anne MacGregor
Keyword(s):  
Clinical Data ◽  
Therapeutic Option ◽  
Calcitonin Gene Related Peptide ◽  
Potential Treatment ◽  
Acute Migraine ◽  
Related Peptide ◽  
Calcitonin Gene

Telcagepant (MK0974) is one of several calcitonin-gene-related peptide antagonists in development as a potential treatment for acute migraine attacks and is the first orally available drug in this class. Preclinical and clinical data are reviewed, which support the efficacy and tolerability of telcagepant for the treatment of migraine, particularly for patients unable to tolerate, or who have cardiovascular contraindications to, triptans.

scholarly journals Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma

Liver Cancer ◽  
2021 ◽  
pp. 1-16
Author(s):  
Xin Hui Chew ◽  
Rehena Sultana ◽  
Eshani N. Mathew ◽  
David Chee Eng Ng ◽  
Richard H.G. Lo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Clinical Outcomes ◽  
Real World ◽  
Compliance Rate ◽  
Locally Advanced ◽  
Consensus Guidelines ◽  
Real World Data ◽  
World Data ◽  
Cancer Centre

<b><i>Introduction:</i></b> Real-world management of patients with hepatocellular carcinoma (HCC) is crucially challenging in the current rapidly evolving clinical environment which includes the need for respecting patient preferences and autonomy. In this context, regional/national treatment guidelines nuanced to local demographics have increasing importance in guiding disease management. We report here real-world data on clinical outcomes in HCC from a validation of the Consensus Guidelines for HCC at the National Cancer Centre Singapore (NCCS). <b><i>Method:</i></b> We evaluated the NCCS guidelines using prospectively collected real-world data, comparing the efficacy of treatment received using overall survival (OS) and progression-free survival (PFS). Treatment outcomes were also independently evaluated against 2 external sets of guidelines, the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC). <b><i>Results:</i></b> Overall treatment compliance to the NCCS guidelines was 79.2%. Superior median OS was observed in patients receiving treatment compliant with NCCS guidelines for early (nonestimable vs. 23.5 months <i>p</i> &#x3c; 0.0001), locally advanced (28.1 vs. 22.2 months <i>p</i> = 0.0216) and locally advanced with macrovascular invasion (10.3 vs. 3.3 months <i>p</i> = 0.0013) but not for metastatic HCC (8.1 vs. 6.8 months <i>p</i> = 0.6300), but PFS was similar. Better clinical outcomes were seen in BCLC C patients who received treatment compliant with NCCS guidelines than in patients with treatment only allowed by BCLC guidelines (median OS 14.2 vs. 7.4 months <i>p</i> = 0.0002; median PFS 6.1 vs. 4.0 months <i>p</i> = 0.0286). Clinical outcomes were, however, similar for patients across all HKLC stages receiving NCCS-recommended treatment regardless of whether their treatment was allowed by HKLC. <b><i>Conclusion:</i></b> The high overall compliance rate and satisfactory clinical outcomes of patients managed according to the NCCS guidelines confirm its validity. This validation using real-world data considers patient and treating clinician preferences, thus providing a realistic analysis of the usefulness of the NCCS guidelines when applied in the clinics.

Radical Cancer Treatment is Safe During COVID-19: The Real World Experience of a Large London-Based Comprehensive Cancer Centre During the First Wave

2021 ◽  
Author(s):  
Beth Russell ◽  
Charlotte L. Moss ◽  
Maria Monroy-Inglesias ◽  
Graham Roberts ◽  
Harvey Dickinson ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Real World ◽  
The Real ◽  
Cancer Centre ◽  
Comprehensive Cancer Centre

scholarly journals The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia

2019 ◽  
Vol 49 (8) ◽  
pp. 1001-1006
Author(s):  
Linda Mileshkin ◽  
Catherine Dunn ◽  
Hannah Cross ◽  
Mary Duffy ◽  
Mark Shaw ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Audit ◽  
Cancer Centre ◽  
Audit Data ◽  
The Uk ◽  
Comprehensive Cancer Centre

scholarly journals Hospital Doctors’ Smoking Behavior and Attitude towards Smoking Cessation Interventions for Patients: A Survey in an Italian Comprehensive Cancer Centre

2016 ◽  
Vol 102 (3) ◽  
pp. 244-251 ◽  
Author(s):  
Micaela Lina ◽  
Roberto Mazza ◽  
Claudia Borreani ◽  
Cinzia Brunelli ◽  
Elisabetta Bianchi ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Smoking Behavior ◽  
Cancer Centre ◽  
Hospital Doctors ◽  
Comprehensive Cancer Centre

Pain Management Needs Assessment: A Survey of Radiation Therapists at a Large Academic Comprehensive Cancer Centre

2012 ◽  
Vol 43 (4) ◽  
pp. 214-220.e2 ◽  
Author(s):  
Lisa Di Prospero ◽  
Nemica Thavarajah ◽  
Emily Chen ◽  
Florencia Jon ◽  
Edward Chow ◽  
...  
Keyword(s):  
Pain Management ◽  
Needs Assessment ◽  
Cancer Centre ◽  
Comprehensive Cancer Centre
Sign in / Sign up

Export Citation Format

Share Document